IMMUNOSTICS, INC. – Trademark Portfolio
Entity Type: 03
IMMUNOSTICS, INC. holds 33 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 19 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 4 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include SPECIFIC, DEVEL-A-TAB, and EARLY DISCOVERY. The owner is based in OCEAN, NJ.
1750 BRIELLE AVE.
OCEAN, NJ 07712
Showing of trademarks Trademarks
Trademark Classifications
IMMUNOSTICS, INC.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does IMMUNOSTICS, INC. have?
IMMUNOSTICS, INC. has 33 U.S. trademarks filed with the USPTO. Of these, 3 registered, 19 abandoned, 11 cancelled.
What trademark classes does IMMUNOSTICS, INC. file in?
IMMUNOSTICS, INC. files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 1 (Chemicals), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are IMMUNOSTICS, INC.'s most well-known trademarks?
IMMUNOSTICS, INC.'s registered trademark portfolio includes well-known marks such as SPECIFIC, DEVEL-A-TAB, and EARLY DISCOVERY. These are among 3 currently registered trademarks in the portfolio.
What is IMMUNOSTICS, INC.'s trademark registration success rate?
IMMUNOSTICS, INC. has a 9% trademark registration rate, with 3 out of 33 resolved applications resulting in successful registration. Currently, 0 applications are pending review.